Sara M. Tolaney, MD, MPH

Articles

Brief Review of SERM Therapy Data in HR+ Metastatic Breast Cancer

October 11th 2022

Closing out their review of endocrine therapy in HR+ metastatic breast cancer, panelists consider clinical trial data with selective estrogen receptor modulators [SERMs].

What is the Role of Oral SERD Therapy in HR+ Metastatic Breast Cancer?

October 4th 2022

Comprehensive insight to the development and use of selective estrogen receptor degraders [SERDs] in HR+ metastatic breast cancer treatment.

HR+ Metastatic Breast Cancer: Overview of the Current Treatment Landscape

October 4th 2022

Opening their discussion on the HR+ metastatic breast cancer treatment landscape, expert oncologists share a broad overview of treatment modalities in this setting.

Future Directions in the Management of HER2+ Breast Cancer

June 29th 2022

Before closing out the discussion on the management of HER2+ breast cancer, experts share their excitement on future treatment strategies.

Patient Profile 5: Strategies for Managing Elevated Liver Function Tests in Patients on the HER2CLIMB Regimen

June 22nd 2022

Experts consider how best to manage adverse events associated with the HER2CLIMB regimen in the setting of HER2+ metastatic breast cancer.

Patient Profile 4: Managing AEs in Patients Receiving Treatment for HER2+ BC

June 22nd 2022

A brief discussion on optimally managing adverse events while treating patients with HER2+ breast cancer.

Patient Profile 4: Strategies for Managing ILD in Patients Receiving Trastuzumab Deruxtecan

June 15th 2022

Sara Tolaney, MD, provides practical advice for managing interstitial lung disease in patients with metastatic HER2+ breast cancer.

Patient Profile 3: Treatment Sequencing in a Patient with metastatic HER2+ Breast Cancer

June 15th 2022

Shared insight on factors for selecting therapy in a patient with HER2+ metastatic breast cancer progressing through multiple lines of therapy.

Patient Profile 3: 43-Year-Old Woman With Metastatic Breast Cancer Progressing Through Multiple Lines of Therapy

June 8th 2022

Expert oncologist Rena Callahan, MD, shares a real-world clinical scenario of a 43-year-old woman with metastatic breast cancer who progressed through multiple lines of therapy.

Patient Profile 2: Treatment Sequencing in a Patient with Progressive Brain Metastases

June 8th 2022

Expert perspectives on use of trastuzumab deruxtecan in patients with HER2+ breast cancer who develop brain metastases.

Patient Profile 2: Clinical Utility of the HER2CLIMB Regimen for HER2+ mBC

June 1st 2022

Centering discussion on a real-world patient profile, subject matter experts discuss use of the HER2CLIMB regimen in HER2+ breast cancer.

Patient Profile 2: How Should T-DM1 Be Sequenced in HER2+ mBC?

June 1st 2022

Considerations for the role of trastuzumab emtansine in HER2+ breast cancer with the advent of newer HER2-targeted therapies.

Patient Profile 2: Strategies for Managing Brain Metastases in HER2+ Metastatic Breast Cancer

May 26th 2022

Shared insight on strategies for managing brain metastases in patients with HER2+ breast cancer.

Patient Profile 2: 26-Year-Old Woman With Triple Positive Breast Cancer

May 26th 2022

Shanu Modi, MD, presents the clinical scenario of a 26-year-old woman with triple positive breast cancer.

Patient Profile 1: Trastuzumab Deruxtecan for HER2+ Metastatic BC

May 19th 2022

Expert perspectives on the use of trastuzumab deruxtecan in a patient with HER2+ metastatic breast cancer.

Patient Profile 1: 62-Year-Old Woman With Metastatic Breast Cancer

May 19th 2022

Breast medical oncologist, Tiffany Traina, MD, shares a clinical scenario of a patient with HER2+ metastatic breast cancer and discusses her treatment approach in the neoadjuvant, adjuvant, and metastatic settings.

Dr. Tolaney on Pivotal Trials in HER2+ Breast Cancer

March 9th 2022

Sara M. Tolaney, MD, MPH, discusses pivotal trials in HER2-positive breast cancer.

Dr. Tolaney on Potential of Trastuzumab Deruxtecan to Shift to First Line in HER2+ Breast Cancer

March 4th 2022

Sara M. Tolaney, MD, MPH, discusses the efficacy of trastuzumab deruxtecan in the second-line setting and its potential to move into the first-line treatment of HER2-positive breast cancer.

Dr. Tolaney on the Efficacy of Zanidatamab Plus Chemo in HER2+ Breast Cancer

January 14th 2022

Sara M. Tolaney, MD, MPH, sheds light on zanidatamab and the data reported with the agent in combination with chemotherapy for the treatment of patients with HER2-positive breast cancer.

Dr. Tolaney on the Importance of Evaluating Enobosarm in ER+ Breast Cancer

January 5th 2022

Sara M. Tolaney, MD, MPH, chief, discusses the importance of evaluating enobosarm in metastatic estrogen receptor–positive, HER2-negative breast cancer.